A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT
A phase 3 trial of Pexidartinib in tenosynovial giant cell tumour, run by Daiichi Sankyo Co., Ltd., active and no longer recruiting.
Overview
A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT is a phase 3 interventional study registered as NCT04488822 by Daiichi Sankyo Co., Ltd., with 40 participants enrolled, started 2020-09-25 and due to reach its primary completion in 2021-10-27. Interventions recorded: Pexidartinib. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialStudy of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
Shares Tenosynovial giant cell tumour (TGCT) and the tag pipeline.
- TrialFirst-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Shares Daiichi Sankyo and the tag pipeline.
- TrialA First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Shares Daiichi Sankyo and the tag pipeline.
- TrialStudy of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)
Shares Tenosynovial giant cell tumour (TGCT) and the tag pipeline.
- TrialA Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Shares Daiichi Sankyo and the tag pipeline.
- TrialA Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Shares Daiichi Sankyo and the tag pipeline.
- TrialValemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Shares Daiichi Sankyo and the tag pipeline.
- TrialSubstudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Shares Daiichi Sankyo and the tag pipeline.